【DPHARMA 7148 交流专区】（前名 CCMDBIO）

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2018	30 Jun 2017	30 Jun 2018	30 Jun 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	123,991	117,049	257,250	240,355
2	Profit/(loss) before tax	12,915	12,642	26,170	24,764
3	Profit/(loss) for the period	10,339	9,641	20,986	19,205
4	Profit/(loss) attributable to ordinary equity holders of the parent	10,339	9,653	20,986	19,217
5	Basic earnings/(loss) per share (Subunit)	1.59	1.48	3.22	2.95
6	Proposed/Declared dividend per share (Subunit)	1.50	1.07	1.50	1.07
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7500		0.7400

icy97

产品需求增加 CCM Duopharma第三季净利扬10%
Tan Xue Ying/theedgemarkets.com
November 28, 2018 19:54 pm +08
http://www.theedgemarkets.com/article/产品需求增加-ccm-duopharma第三季净利扬10

（吉隆坡28日讯）私人与公共领域的需求增加，把CCM Duopharma Biotech Bhd截至今年9月杪第三季（2018财年第三季）净利按年推高10.4%至1229万令吉，上财年同季为1113万令吉。

营业额按年上涨9.1%至1亿2584万令吉，上财年同季报1亿1538万令吉。

现财年首9个月净利为3327万令吉，较上财年同期的3033万令吉，按年上升9.7%。营业额则从3亿5573万令吉，按年提高7.7%至3亿8309万令吉。

展望未来，该集团估计可在现财年取得满意的表现，但基于最近美元走强，导致其制造业务面临压力。

截稿时，令吉兑美元报4.2013，为2017年11月9日以来的最低点。

（编译：魏素雯）

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2018	30 Sep 2017	30 Sep 2018	30 Sep 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	125,838	115,379	383,088	355,734
2	Profit/(loss) before tax	15,838	14,207	42,008	38,971
3	Profit/(loss) for the period	12,286	11,127	33,272	30,332
4	Profit/(loss) attributable to ordinary equity holders of the parent	12,286	11,127	33,272	30,332
5	Basic earnings/(loss) per share (Subunit)	1.86	1.75	5.09	4.70
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	1.50	1.07
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7600		0.7400

icy97

Type	Announcement
Subject	OTHERS
Description	CCM DUOPHARMA MAINTAINS POSITIVE RESULT FOR Q3 FY 2018
We attach herewith a copy of press release dated 29 November 2018. This announcement is dated 29 November 2018. Please refer to the attachment below.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5989761

Attachments PRESS RELEASE - CCM DUOPHARMA MAINTAINS POSITIVE RESULT FOR Q3 FY 2018.pdf

icy97

icy97 发表于 16-2-2017 05:30 AM
CCM Duopharma寻求销售用于肾衰竭治疗的促红细胞生成素
By Sulhi Azman  / theedgemarkets.com   | February 15, 2017 : 8:11 PM MYT

（吉隆坡15日讯）CCM Duopharma Biotech Bhd将为促红细胞生成素（EPO）生物 ...

Type	Announcement
Subject	OTHERS
Description	SUCCESSFUL PRODUCT REGISTRATION FOR ERYSAA (AN ERYTHROPOIETIN PRODUCT)
We refer to the announcement made by the Company on 15 February 2017 on the successful completion of jointly conducted multinational Phase III Clinical Trial for erythropoietin (hereinafter referred to as the ‘Successful Joint Clinical Trial Announcement’). The terms used herein, unless the context otherwise stated, bear the same meaning as those defined in the Successful Joint Clinical Trial Announcement. As highlighted in the Successful Joint Clinical Trial Announcement, the erythropoietin (EPO) product code-named as “PDA10” (and now given the commercial un-coded name ‘ERYSAA’) will be launched in the Malaysia market upon receiving the marketing authorisation from the National Pharmaceutical Regulatory Agency (“NPRA”), Ministry of Health Malaysia. CCM Duopharma Biotech Berhad is pleased to announce that its wholly-owned subsidiary, Duopharma (M) Sendirian Berhad (“DMSB”), has on 7 February 2019 received from the NPRA the Notice of Approval of Product Registration dated 7 February 2019 notifying on the approval of product registration for ‘ERYSAA’ (i.e. PDA10) in Malaysia. The product registration is valid from 31 January 2019 until 31 January 2024. Under the Joint Clinical Trial & License And Distribution Agreement entered into between PanGen Biotech, Inc. (“PanGen”) and DMSB in 2012, DMSB obtained exclusive license to package, fill & finish, and distribute the EPO product in Malaysia, Singapore and Brunei (and such other countries as mutually agreed by the parties to the Agreement). This announcement is dated 7 February 2019.

icy97

ype	Announcement
Subject	OTHERS
Description	CCM DUOPHARMA BIOTECH BERHAD ("CCM DUOPHARMA" OR "THE COMPANY") - FINAL DIVIDEND
The Board of Directors of CCM Duopharma is pleased to propose a single-tier final dividend of 4 sen per CCM Duopharma Share in respect of the financial year ending 31 December 2018 subject to the following:- shareholders’ approval for the said proposed single-tier final dividend; and shareholders’ approval for the issuance of new CCM Duopharma shares pursuant to the Dividend Reinvestment Plan (“DRP”) that was approved at the Company’s Extraordinary General Meeting held on 31 May 2018 that provides the shareholders of the Company with the option to elect to reinvest their dividend in new CCM Duopharma shares (“Issuance of New CCM Duopharma Shares Pursuant To The DRP”). [The single-tier final dividend is not taxable in the hands of the receiving shareholders.] Subject to the shareholders’ approval for the proposed single-tier final dividend and the shareholders’ approval for the Issuance of New CCM Duopharma Shares pursuant to the DRP to be obtained at the forthcoming Annual General Meeting of the Company, the Board of Directors has resolved that the Dividend Reinvestment Plan would apply to the final dividend. The entitlement date, payment date and electable portion of the proposed single-tier final dividend will be announced on a later date. The final dividend, if approved, will be paid no later than 3 months from the date of the shareholders’ approval for the aforesaid matters pursuant to Paragraph 8.26 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. This announcement is dated 18 February 2019.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2018	31 Dec 2017	31 Dec 2018	31 Dec 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	115,634	112,253	498,722	467,987
2	Profit/(loss) before tax	17,658	12,801	59,666	51,772
3	Profit/(loss) for the period	14,369	12,131	47,641	42,463
4	Profit/(loss) attributable to ordinary equity holders of the parent	14,369	12,131	47,641	42,463
5	Basic earnings/(loss) per share (Subunit)	2.17	1.86	7.26	6.52
6	Proposed/Declared dividend per share (Subunit)	4.00	2.57	5.50	3.64
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7300		0.7400

icy97

Type	Announcement
Subject	OTHERS
Description	CCM DUOPHARMA UNVEILS "DUOPHARMA"
We attach herewith a copy of press release dated 20 February 2019. Please refer attachment below. This announcement is dated 20 February 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6068161

Attachments Duopharma Rebranding News Release_ Change of Name (MOM)_approved.pdf

icy97

CCMDBIO - CHANGE OF NAME

CCM DUOPHARMA BIOTECH BERHAD

Kindly be advised that the aforesaid Company has changed its name to DUOPHARMA BIOTECH BERHAD. As such, the Company’s shares will be traded and quoted under the new name with effect from 9.00 a.m., Monday, 4 March 2019.

The Stock Short Name will be changed as follows:-

Old Name	New Name	Old Stock Short Name	New Stock Short Name
CCM DUOPHARMA BIOTECH BERHAD	DUOPHARMA BIOTECH BERHAD	CCMDBIO	DPHARMA

However, the Stock Number remains unchanged.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2019	31 Mar 2018	31 Mar 2019	31 Mar 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	150,386	133,259	150,386	133,259
2	Profit/(loss) before tax	18,786	13,255	18,786	13,255
3	Profit/(loss) for the period	14,465	10,647	14,465	10,647
4	Profit/(loss) attributable to ordinary equity holders of the parent	14,465	10,647	14,465	10,647
5	Basic earnings/(loss) per share (Subunit)	2.19	1.64	2.19	1.64
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7500		0.7300

icy97

DUOPHARMA BIOTECH BERHAD

EX-date	26 Jun 2019
Entitlement date	27 Jun 2019
Entitlement time	05:00 PM
Entitlement subject	Final Dividend (with Dividend Re-Investment Plan)
Entitlement description	Final Single-Tier Dividend of RM0.04 per ordinary share
Period of interest payment	to
Financial Year End	31 Dec 2018
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	Tricor Investor & Issuing House Services Sdn BhdUnit 32-01, Level 32, Tower A, Vertical Business SuiteAvenue 3, Bangsar SouthNo. 8, Jalan Kerinchi59200 Kuala LumpurTel No. : 03-2783 9299Fax No. : 03-2783 9222
Payment date	26 Jul 2019
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	27 Jun 2019
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.04
Par Value (if applicable)

Remarks :

The Board of Directors of Duopharma Biotech Berhad ("Duopharma" or the "Company") ("Board") has proposed final single-tier dividend of RM0.04 per ordinary share in Duopharma ("Duopharma Shares") ("Dividend") for the financial year ended 31 December 2018. On 31 May 2019, the shareholders of Duopharma had at the Company's Eighteenth Annual General Meeting approved the Dividend and authorised the Board to allot and issue such number of new Duopharma Shares from time to time as may be required to be allotted and issued pursuant to the dividend reinvestment plan ("DRP"). On behalf of the Board, UOB Kay Hian Securities (M) Sdn Bhd had, on 13 June 2019, announced that the issue price of the new Duopharma Shares to be issued pursuant to the implementation of the DRP has been fixed at RM1.20 per Duopharma Share. This announcement is dated 13 June 2019.

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) OTHER ISSUE OF SECURITIES
Description	DUOPHARMA BIOTECH BERHAD ("DUOPHARMA" OR "THE COMPANY") DIVIDEND REINVESTMENT PLAN THAT PROVIDES THE SHAREHOLDERS OF DUOPHARMA THE OPTION TO ELECT TO REINVEST THEIR CASH DIVIDEND IN NEW ORDINARY SHARES IN DUOPHARMA ("DRP")
The terms used herein, unless expressly stated otherwise or where the context requires otherwise, bear the same meaning as those defined in the earlier announcements in relation to the DRP. We refer to our earlier announcements dated 18 February 2019, 10 June 2019, 12 June 2019, 13 June 2019 and 1 July 2019 in relation to the DRP. On behalf of the Board, UOB Kay Hian Securities (M) Sdn Bhd wishes to announce that based on the valid dividend reinvestment forms received by Tricor Investor & Issuing House Services Sdn Bhd, being share registrar of the Company for the DRP, Duopharma will be issuing 18,225,450 new Duopharma Shares pursuant to the DRP ("New Shares"). The New Shares to be issued represent approximately 82.62% of the total number of 22,059,273 New Shares that would have been issued pursuant to the DRP had all the entitled shareholders of Duopharma elect to reinvest their respective Electable Portions of their cash dividend in New Shares. Barring any unforeseen circumstances, the said New Shares pursuant to the DRP are expected to be listed on the Main Market of Bursa Malaysia Securities Berhad on 29 July 2019. This announcement is dated 19 July 2019.

icy97

DUOPHARMA BIOTECH BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Others
Details of corporate proposal	Dividend Reinvestment Plan that provides the shareholders of Duopharma with an option to elect to reinvest their single-tier final dividend of RM0.04 per ordinary share in Duopharma ("Duopharma Share(s)") for the financial year ended 31 December 2018 in new Duopharma Shares
No. of shares issued under this corporate proposal	18,225,450
Issue price per share ($$)	Malaysian Ringgit (MYR)   1.2000
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)
Latest issued share capital after the above corporate proposal in the following
Units	680,106,506
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 369,059,192.000
Listing Date	29 Jul 2019

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2019	30 Jun 2018	30 Jun 2019	30 Jun 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	145,466	123,991	295,852	257,250
2	Profit/(loss) before tax	18,316	12,915	37,102	26,170
3	Profit/(loss) for the period	13,916	10,339	28,381	20,986
4	Profit/(loss) attributable to ordinary equity holders of the parent	13,916	10,339	28,381	20,986
5	Basic earnings/(loss) per share (Subunit)	2.07	1.59	4.26	3.22
6	Proposed/Declared dividend per share (Subunit)	1.00	1.50	1.00	1.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.7600		0.7300

icy97

Type	Announcement
Subject	OTHERS
Description	DUOPHARMA BIOTECH BERHAD (FORMERLY KNOWN AS CCM DUOPHARMA BIOTECH BERHAD) (DUOPHARMA BIOTECH OR THE COMPANY)  INTERIM DIVIDEND
The Board of Directors of Duopharma Biotech is pleased to declare a single-tier interim dividend of 1 sen per ordinary share in Duopharma Biotech (“Duopharma Biotech Share”) in respect of the financial year ending 31 December 2019 (preceding year corresponding quarter ended 30 June 2018: single-tier interim dividend of 1.5 sen per Duopharma Biotech Share). The lower interim dividend in comparison to the corresponding period in the previous year was to allow for more cash in order to fund existing business expansion and also working capital purposes. The Board of Directors has resolved that the Dividend Reinvestment Plan (“DRP”), which provides the shareholders of the Company with the option to elect to reinvest their dividend in new Duopharma Biotech Shares, would apply to the interim dividend. The entitlement date, payment date and electable portion of the single-tier interim dividend will be announced on a later date. The single-tier interim dividend is not taxable in the hands of the receiving shareholders. The interim dividend will be paid no later than 3 months from the date of declaration (i.e. by 30 November 2019) pursuant to Paragraph 8.26 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. This announcement is dated 30 August 2019.

icy97

Type	Announcement
Subject	OTHERS
Description	Duopharma Biotech Declares 1.0 Sen Interim Dividend For H1 FY2019
We attach herewith a copy of press release dated 30 August 2019. Please refer attachment below. This announcement is dated 30 August 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6272133

Attachments NEWS RELEASE _ DUOPHARMA BIOTECH DECLARES 1.0 SEN INTERIM DIVIDEND FOR H1 FY2019.pdf

icy97

政府合约保健业务带动·联合药业前景亮丽
https://www.sinchew.com.my/content/content_2114748.html

（吉隆坡11日讯）联合药业（DPHARMA,7148,主板医疗保健组）预期可获政府更新药物采购合约，以及消费者保健业务料双位数强劲增长，分析员上调财测并持续看好该公司前景。

达证券出席联合药业的分析员汇报会后表示，针对政府投标合约及发马的特许权，即将于11月届满，以往需6至7月周期进行投标，由于如今时间有限，管理层相信政府会沿续现有合约及药物价格一年。

52%收入来自政府合约

该行认为这对联合药业有利，其52%收入是来自政府合约。

至于胰岛素投标合约也在今年11月届满，管理层已和卫生部洽谈以续约两年，管理层表示目前回应正面，希望可在60天内有下文。

在即将到来的2020年财政预算案，管理层希望政府重新提供再投资补贴，该补贴在去年预算案未获更新。该公司今年上半年的税率为23.5%，相比去年为20.2%。

管理层并透露，未来2至3年，消费者保健业务营收将达逾1亿令吉，目前为7500万令吉。

联合药业上半年税后盈利成长35.2%至2840万令吉，管理层预见私人领域的消费将减少，因经济不佳，病人转至政府医院看病，但该行表示，政府需求已提高，预期整体药物需求仍保持韧性。

该行预期该公司第三季将更强劲，盈利有望增长逾25%，因适逢政府采购时机和需求强劲。

该行在调高销售和赚幅假设后，将2019、2020及2021年财测分别调高5.2%、5.2%和2.7%。

但将2019年税率预测从21%调高至23.5%，目标价从1令吉62仙上调至1令吉70仙。保持买进评级。

文章来源 ： 星洲日报 2019-09-12

icy97

DUOPHARMA BIOTECH BERHAD

EX-date	15 Oct 2019
Entitlement date	16 Oct 2019
Entitlement time
Entitlement subject	Interim Dividend (with Dividend Re-Investment Plan)
Entitlement description	Interim dividend of RM0.01 per ordinary share
Period of interest payment	to
Financial Year End	31 Dec 2019
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200 Kuala LumpurTel No: (603) 2783 9299Fax No: (603) 2783 9222
Payment date	14 Nov 2019
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	16 Oct 2019
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.01
Par Value (if applicable)

Remarks :

The Board of Directors of Duopharma Biotech Berhad ("Duopharma Biotech" or the "Company") ("Board") has declared a single-tier interim dividend of RM0.01 per ordinary share in Duopharma Biotech ("Duopharma Biotech Shares") in respect of the financial year ending 31 December 2019. The Board has also determined the dividend reinvestment plan ("DRP") would apply to the interim dividend.Following the above, on behalf of the Board, Mercury Securities Sdn Bhd had on 2 October 2019 announced that the issue price of the new Duopharma Biotech Shares to be issued pursuant to the DRP has been fixed at RM1.25 per Duopharma Biotech Share.This announcement is dated 2 October 2019.

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) OTHER ISSUE OF SECURITIES
Description	DUOPHARMA BIOTECH BERHAD (FORMERLY KNOWN AS CCM DUOPHARMA BIOTECH BERHAD) ("DUOPHARMA BIOTECH" OR THE "COMPANY")DIVIDEND REINVESTMENT PLAN ("DRP")
We refer to the announcements made on 30 August 2019, 25 September 2019, 1 October 2019 and 2 October 2019 in relation to the DRP (“Announcements”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcements unless otherwise defined herein. On behalf of the Board, Mercury Securities wishes to announce that based on the valid dividend reinvestment forms received by Tricor Investor & Issuing House Services Sdn Bhd, being the share registrar of the Company for the DRP, Duopharma Biotech will be issuing 4,276,658 new Duopharma Biotech Shares (“New Shares”) pursuant to the DRP. The New Shares to be issued represent approximately 78.65% of the total number of 5,437,740 New Shares that would have been issued pursuant to the DRP had all the entitled shareholders of Duopharma Biotech elected to reinvest their respective Electable Portions of their cash dividend into New Shares. Barring any unforeseen circumstances, the said New Shares pursuant to the DRP are expected to be listed on the Main Market of Bursa Securities on 15 November 2019. This announcement is dated 6 November 2019.

icy97

DUOPHARMA BIOTECH BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Others
Details of corporate proposal	Dividend Reinvestment Plan applicable to the interim single-tier cash dividend of RM0.01 per ordinary share in Duopharma Biotech Berhad for the financial year ending 31 December 2019
No. of shares issued under this corporate proposal	4,276,658
Issue price per share ($$)	Malaysian Ringgit (MYR)   1.2500
Par Value($$) (if applicable)
Latest issued share capital after the above corporate proposal in the following
Units	684,383,164
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 374,405,014.500
Listing Date	15 Nov 2019

icy97

Type	Announcement
Subject	OTHERS
Description	CONTRACT FOR THE SUPPLY OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS TO HOSPITALS, CLINICS AND OTHERS UNDER THE GOVERNMENT OF MALAYSIA FOR APPL 2017-2019 VIDE SUPPLY AGREEMENTS ("Supply Agreements") BETWEEN PHARMANIAGA LOGISTICS SDN BHD AND DUOPHARMA (M) SENDIRIAN BERHAD ("Supplier")(Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
Duopharma Biotech Berhad (the “Company”) wishes to announce that its wholly-owned subsidiary, Duopharma (M) Sendirian Berhad ("DMSB") has received a letter from Pharmaniaga Logistics Sdn. Bhd. ("PLSB"), notifying DMSB that the Contract Period of the Supply Agreements for the supply of pharmaceutical and/or non-pharmaceutical products by DMSB to hospitals, clinics and others under the Government of Malaysia have been extended for twenty-five (25) months, commencing 1 December 2019 until 31 December 2021. The Supply Agreements are in the ordinary course of business of the Company. This announcement is dated 25 November 2019.